Test Catalog

Test Id : MLHPB

MLH1 Hypermethylation Analysis, Blood

Useful For
Suggests clinical disorders or settings where the test may be helpful

As an adjunct to positive hypermethylation in tumor to distinguish between somatic and germline hypermethylation

 

As an adjunct to negative MLH1 germline testing in cases where colon or endometrial tumor demonstrates microsatellite instability-H (MSI-H) and loss of MLH1 protein expression

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

For information see Lynch Syndrome Testing Algorithm.

Method Name
A short description of the method used to perform the test

Polymerase Chain Reaction (PCR)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

MLH1 Hypermethylation Analys, Blood

Aliases
Lists additional common names for a test, as an aid in searching

Hypermethylation

MLH1 Hypermethylation

MLHBL

Promoter Hypermethylation

Constitutional MLH1 promoter hypermethylation

Germline MLH1 promoter hypermethylation

CMPH

Lynch syndrome

HNPCC

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

For information see Lynch Syndrome Testing Algorithm.

Specimen Type
Describes the specimen type validated for testing

Varies

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

 

Submit only 1 of the following specimens:

 

Specimen Type: Whole blood

Container/Tube: Lavender top (EDTA) or yellow top (ACD)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated 4 days/Frozen 4 days

Additional Information:

1. Specimens are preferred to be received within 4 days of collection. Extraction will be attempted for specimens received after 4 days, and DNA yield will be evaluated to determine if testing may proceed.

2. To ensure minimum volume and concentration of DNA is met, the requested volume must be submitted. Testing may be canceled if DNA requirements are inadequate.

 

Specimen Type: Cord blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send cord blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated 4 days/Frozen 4 days

Additional Information:

1. Specimens are preferred to be received within 4 days of collection. Extraction will be attempted for specimens received after 4 days, and DNA yield will be evaluated to determine if testing may proceed.

2. To ensure minimum volume and concentration of DNA is met, the requested volume must be submitted. Testing may be canceled if DNA requirements are inadequate.

3. While a properly collected cord blood sample may not be at risk for maternal cell contamination, unanticipated complications may occur during collection. Therefore, maternal cell contamination studies are recommended to ensure the test results reflect that of the patient tested and are available at an additional charge. Order MATCC / Maternal Cell Contamination, Molecular Analysis, Varies on the maternal specimen.

 

Specimen Type: Extracted DNA

Container/Tube:

Preferred: Screw Cap Micro Tube, 2 mL with skirted conical base

Acceptable: Matrix tube, 1 mL

Collection Instructions:

1. The preferred volume is at least 100 mcL at a concentration of 75 ng/mcL.

2. Include concentration and volume on tube.

Specimen Stability Information: Frozen (preferred) 1 year/Ambient/Refrigerated

Additional Information: DNA must be extracted in a CLIA-certified laboratory or equivalent and must be extracted from a specimen type listed as acceptable for this test (including applicable anticoagulants). Our laboratory has experience with Chemagic, Puregene, Autopure, MagnaPure, and EZ1 extraction platforms and cannot guarantee that all extraction methods are compatible with this test. If testing fails, one repeat will be attempted, and if unsuccessful, the test will be reported as failed and a charge will be applied. If applicable, specific gene regions that were unable to be interrogated due to DNA quality will be noted in the report.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file.

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T576)

2. Molecular Genetics: Inherited Cancer Syndromes Patient Information (T519)

3. If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

See Specimen Requirements

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

All specimens will be evaluated by Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Varies Varies

Useful For
Suggests clinical disorders or settings where the test may be helpful

As an adjunct to positive hypermethylation in tumor to distinguish between somatic and germline hypermethylation

 

As an adjunct to negative MLH1 germline testing in cases where colon or endometrial tumor demonstrates microsatellite instability-H (MSI-H) and loss of MLH1 protein expression

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

For information see Lynch Syndrome Testing Algorithm.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

The lifetime risk of colorectal cancer in the general population is 4% to 6%.(1) Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) is an autosomal dominant hereditary cancer syndrome accounting for 2% to 4% of all colorectal cancer cases.(2,3)

 

Lynch syndrome is associated with germline variants in the mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and PMS2, or deletions of the EPCAM gene. It is predominantly characterized by significantly increased risks for colorectal and endometrial cancer.(2,3) The lifetime risk for cancer is highly variable and dependent on the gene involved. Other malignancies within the tumor spectrum include gastric, ovarian, and small bowel cancers and hepatobiliary and upper urinary tract carcinomas.(2,3)

 

Several laboratory-based strategies may be utilized to screen for Lynch syndrome, including testing tumor tissue for the presence of microsatellite instability (MSI-H) and assessment of protein expression of MMR proteins (MLH1, MSH2, MSH6, PMS2) by immunohistochemistry (IHC).

 

Defective MMR in sporadic colon cancer is most often due to molecular variation in MLH1, of which promoter hypermethylation (epigenetic silencing) constitutes the most common cause of MLH1 inactivation. A somatic-occurring variant in the BRAF gene (V600E) is present in approximately 70% of tumors with hypermethylation of the MLH1 promoter. Importantly, the V600E variant is rarely identified in cases with disease-causing germline MLH1 variants.

 

While most MLH1 promoter hypermethylation occurs sporadically, some individuals with tumor hypermethylation may have germline inactivation of the MLH1 gene via constitutional promoter hypermethylation. This condition is known as constitutional MLH1 promoter hypermethylation, which is consistent with a diagnosis of Lynch syndrome.(4-7) In contrast to sequence variants in MLH1, current evidence suggests that the risk of transmitting constitutional MLH1 promoter hypermethylation is less than50%. As such, these individuals may not have a strong family history of Lynch-related cancers and often test negative on traditional germline sequencing panels. Thus, testing for constitutional MLH1 promoter hypermethylation may be considered if there is still suspicion for an inherited etiology following negative germline testing for patients with MLH1 promoter methylated tumors.

 

For more information see Lynch Syndrome Testing Algorithm

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Interpretive report will be provided.

Interpretation
Provides information to assist in interpretation of the test results

The report will include specimen information, assay information, and interpretation of test results.

 

Absence of hypermethylation is reported as not providing evidence for germline (constitutional) MLH1 promoter hypermethylation. Presence of hypermethylation is reported as consistent with germline (constitutional) inactivation of MLH1 by promoter hypermethylation.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in the interpretation of results may occur if requested information is inaccurate or incomplete.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review. 1975-2018. National Cancer Institute. Updated April 2021. Accessed March 24, 2025. Available at: https://seer.cancer.gov/csr/1975_2018

2. Gupta S, Provenzale D, Llor X, et al. NCCN Guidelines Insights: Genetic/familial high-risk assessment: colorectal, version 2.2019. J Natl Compr Canc Netw. 2019;17(9):1032-1041

3. Idos G, Valle L. Lynch syndrome. In: Adam MP, Everman DB, Mirzaa GM, et al, eds. GeneReviews (Internet). University of Washington, Seattle; 2004. Updated February 4, 2021. Accessed March 24, 2025. Available at www.ncbi.nlm.nih.gov/books/NBK1211/

4. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet. 2009;46(12):793-802

5. Hitchins M, Williams R, Cheong K, et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology. 2005;129(5):1392-1399

6. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer. 2009;48(8):737-744

7. Valle L, Carbonell P, Fernandez V, et al. MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer. Clin Genet. 2007;71(3):232-237

Method Description
Describes how the test is performed and provides a method-specific reference

A polymerase chain reaction-based assay is used to test normal DNA for the presence of hypermethylation of the MLH1 promoter.(Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001;61[3]:900-902)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Varies

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

8 to 12 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

Whole blood: 30 days (if available); Extracted DNA: 3 months

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

81288

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
MLHPB MLH1 Hypermethylation Analys, Blood 97760-3
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
52906 Result Summary 50397-9
52907 Result 82939-0
52908 Interpretation 69047-9
52909 Reason for Referral 42349-1
52910 Specimen 31208-2
52911 Source 31208-2
52912 Released By 18771-6

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports

Test Update Resources

Change Type Effective Date
Test Changes - Specimen Information 2025-05-22